Open Access
Med Buccale Chir Buccale
Volume 17, Number 3, Août 2011
Page(s) 177 - 183
Section Articles originaux / Original articles
Published online 15 June 2011
  1. Navazesh M, Mulligan R, Komaroff E, Redford M, Greenspan D, Phelan JA. The prevalence of xerostomia and salivary gland hypofunction in a cohort of HIV-positive and at-risk women. J Dent Res 2000;79:1502-07. [CrossRef] [PubMed]
  2. Kozinetz CA, Carter AB, Simon C, Hicks MJ, Rossmann SN, Flaitz CM, Cron SG, Kline MW. Oral manifestations of pediatric vertical HIV infection. AIDS Patient Care STDS 2000;14:89-94. [CrossRef] [PubMed]
  3. Laskaris G, Hadjivassiliou M, Stratigos J. Oral signs and symptoms in 160 Greek HIV-infected patients. J Oral Pathol Med 1992;21:120-3. [CrossRef] [PubMed]
  4. Lin AL, Johnson DA, Stephan KT, Yeh CK. Alteration in salivary function in early HIV infection. J Dent Res 2003;82:719-24. [CrossRef] [PubMed]
  5. Navazesh M, Mulligan R, Barron Y, Redford M, Greenspan D, Alves M, Phelan JA. 4-year longitudinal evaluation of xerostomia and salivary gland hypofunction in the Women’s Interagency HIV Study participants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;95:693-8. [CrossRef] [PubMed]
  6. Navazesh M, Mulligan R, Karim R, Mack W J. Effect of HAART on salivary gland function in the women s interagency HIV study (WIHS). Oral Dis 2009;15:52-60. [CrossRef] [PubMed]
  7. Zannou D M, Houngbe F, Acapko J, Ade G. Effets indésirables des thérapies antirétrovirales observés chez des patients infectés par le VIH à Cotonou, Bénin. Mali Méd 2007;12:37-43.
  8. Scully C, Diz Dios P. Orofacial effects of antiretroviral therapies. Oral Dis 2001;7:205-10. [CrossRef] [PubMed]
  9. Ship JA, Fox PC, Baum BJ. How much saliva is enough? "Normal" function defined. J Am Dent Assoc 1991;122:63-9.
  10. Olive A, Salavert A, Manriquez M, Clotet B, Moragas A. Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors. Ann Rheum Dis 1998;57:749. [CrossRef]
  11. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 1987;66:648-53. [PubMed]
  12. Lin AL, Johnson DA, Sims CA, Stephan KT, Yeh CK. Salivary gland function in HIV-infected patients treated with highly active antiretroviral therapy (HAART). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:318-24. [CrossRef] [PubMed]
  13. Aguirre-Urizar JM, Echebarria-Goicouria MA, Eguia-del-Valle A. Acquired immunodeficiency syndrome: manifestations in the oral cavity. Med Oral Patol Oral Cir Bucal 2004; 9 Suppl: 153-7. 148-53.
  14. Patton LL, Phelan JA, Ramos-Gomez FJ, Nittayananta W, Shiboski CH, Mbuguye TL. Prevalence and classification of HIV-associated oral lesions. Oral Dis 2002;8 Suppl 2:98-109. [CrossRef] [PubMed]
  15. Ceballos-Salobrena A, Gaitain-Cepeda L, Ceballos-Garcia L, Samaranayake LP. The effect of antiretroviral therapy on the prevalence of HIV associated oral candidiasis in a Spanish cohort. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:345-50. [CrossRef] [PubMed]
  16. Mandel L, Surattanont F. Regression of HIV parotid swellings after antiviral therapy: case reports with computed tomographic scan evidence. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;94:454-9. [CrossRef] [PubMed]
  17. Soberman N, Leonidas JC, Berdon WE, Bonagura V, Haller JO, Posner M, Mandel L. Parotid enlargement in children seropositive for human immunodeficiency virus: imaging findings. AJR Am J Roentgenol 1991;157:553-6. [PubMed]
  18. Schiodt M, Greenspan D, Daniels TE, Nelson J, Leggott PJ, Wara DW, Greenspan JS. Parotid gland enlargement and xerostomia associated with labial sialadenitis in HIV-infected patients. J Autoimmun 1989;2:415-25. [CrossRef] [PubMed]
  19. Vargas PA, Mauad T, Bohm GM, Saldiva PH, Almeida OP. Parotid gland involvement in advanced AIDS. Oral Dis 2003;9:55–61. [CrossRef] [PubMed]
  20. Greenspan J, Greenspan D. The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 2002;8 Suppl 2:34-9. [CrossRef] [PubMed]
  21. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:299-304. [CrossRef] [PubMed]
  22. Lin AL, Johnson DA, Stephan KT, Yeh CK. Salivary secretory leukocyte protease inhibitor increases in HIV infection. J Oral Pathol Med 2004;33:410-6. [CrossRef] [PubMed]
  23. Silverberg MJ, Gore ME, French AL, Gandhi M, Glesby MJ, Kovacs A, Wilson TE, Young MA, Gange SJ. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women’s Interagency HIV Study. Clin Infect Dis 2004;39:717-24. [CrossRef] [PubMed]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.